The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC).
Giovanna Speranza
No relevant relationships to disclose
Robert J. Kinders
No relevant relationships to disclose
Sonny Khin
No relevant relationships to disclose
Marcie K. Weil
No relevant relationships to disclose
Khanh Tu Do
No relevant relationships to disclose
Yvonne Horneffer
No relevant relationships to disclose
Lamin Juwara
No relevant relationships to disclose
Deborah Allen
No relevant relationships to disclose
P. Mickey Williams
No relevant relationships to disclose
Chih Jian Lih
No relevant relationships to disclose
Larry Rubinstein
No relevant relationships to disclose
Laurence A Doyle
No relevant relationships to disclose
James H. Doroshow
No relevant relationships to disclose
Shivaani Kummar
No relevant relationships to disclose